U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840886) titled 'A Study of PHST001 in Advanced Solid Tumors' on Feb. 10.
Brief Summary: PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: PHST001
* PHST001 will be administered as I...